Regulation of EMT by Notch signaling pathway in tumor progression

Current Cancer Drug Targets

Volumn 13, Issue 9, 2013, Pages 957-962

  Li, Yumei ^a   Ma, Jia ^a   Qian, Xiujuan ^a   Wu, Qiong ^a   Xia, Jun ^a   Miele, Lucio ^b   Sarkar, Fazlul H ^c   Wang, Zhiwei ^d,e  

^a BENGBU MEDICAL COLLEGE   (China)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e SOOCHOW UNIVERSITY   (China)

Author keywords

Cancer; MiRNA; Natural compound; Notch; Oncogene; Tumor suppressor gene

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; DELTA LIKE 4 LIGAND; FIBRONECTIN; GAMMA SECRETASE; JAGGED 2; JAGGED1; MATRIX METALLOPROTEINASE; MICRORNA; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANGIOGENESIS; APOPTOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NONHUMAN; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84890828010     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113136660101     Document Type: Review

References (65)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
2. Ranganathan, P.; Weaver, K. L.; Capobianco, A. J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 2011, 11, 338-351.
3. Zoncu, R.; Efeyan, A.; Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12, 21-35.
4. Ng, J. M.; Curran, T. The Hedgehog's tale: developing strategies for targeting cancer. Nat. Rev. Cancer 2011, 11, 493-501.
5. Song, M. S.; Salmena, L.; Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13, 283-296.
6. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8, 627-644.
7. Klaus, A.; Birchmeier, W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 2008, 8, 387-398.
8. Radtke, F.; Raj, K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat. Rev. Cancer 2003, 3, 756-767.
9. Wang, Z.; Li, Y.; Kong, D.; Sarkar, F. H. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr. Drug Targets 2010, 11, 745-751.
10. Grego-Bessa, J.; Diez, J.; Timmerman, L.; de, la. Pompa. J. L. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. Cell Cycle 2004, 3, 718-721.
11. Wang, Z.; Li, Y.; Ahmad, A.; Azmi, A. S.; Banerjee, S.; Kong, D.; Sarkar, F.H. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim. Biophys. Acta 2010, 1806, 258-267.
12. Wang, Z.; Li, Y.; Banerjee, S.; Sarkar, F. H. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 2008, 28, 3621-3630.
13. Wang, Z.; Li, Y.; Banerjee, S.; Sarkar, F. H. Emerging role of Notch in stem cells and cancer. Cancer Lett. 2009, 279, 8-12.
14. Wang, Z.; Li, Y.; Kong, D.; Ahmad, A.; Banerjee, S.; Sarkar, F. H. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett. 2010, 292, 141-148.
15. Pannuti, A.; Foreman, K.; Rizzo, P.; Osipo, C.; Golde, T.; Osborne, B.; Miele, L. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 2010, 16, 3141-3152.
16. Rizzo, P.; Osipo, C.; Foreman, K.; Golde, T.; Osborne, B.; Miele, L. Rational targeting of Notch signaling in cancer. Oncogene 2008, 27, 5124-5131.
17. Kopan, R.; Ilagan, M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137, 216-233.
18. Miele, L. Notch signaling. Clin. Cancer Res. 2006, 12, 1074-1079.
19. Piazzi, G.; Bazzoli, F.; Ricciardiello, L. Epigenetic silencing of Notch signaling in gastrointestinal cancers. Cell Cycle 2012, 11, 4323-4327.
20. Tzoneva, G.; Ferrando, A. A. Recent advances on NOTCH signaling in T-ALL. Curr. Top. Microbiol. Immunol. 2012, 360, 163-182.
21. Stockhausen, M. T.; Kristoffersen, K.; Poulsen, H. S. Notch signaling and brain tumors. Adv. Exp. Med. Biol. 2012, 727, 289-304.
22. Guilmeau, S. Notch signaling and intestinal cancer. Adv. Exp. Med. Biol. 2012, 727, 272-288.
23. Reichrath, J; Reichrath, S. Notch-signaling and nonmelanoma skin cancer: an ancient friend, revisited. Adv. Exp. Med. Biol. 2012, 727, 265-271.
24. Muller, C. S. Notch signaling and malignant melanoma. Adv. Exp. Med. Biol. 2012, 727, 258-264.
25. Reedijk, M. Notch signaling and breast cancer. Adv. Exp. Med. Biol. 2012, 727, 241-257.
26. Guo, S.; Liu, M.; Gonzalez-Perez, R. R. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim. Biophys. Acta. 2011, 1815, 197-213.
27. Sethi, N.; Kang, Y. Notch signalling in cancer progression and bone metastasis. Br. J. Cancer 2011, 105, 1805-1810.
28. De, Craene. B.; Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13, 97-110.
29. Thiery, J. P.; Acloque, H.; Huang, R. Y.; Nieto, M. A. Epithelialmesenchymal transitions in development and disease. Cell 2009, 139, 871-890.
30. Wu, Q.; Hou, X.; Xia, J.; Qian, X.; Miele, L.; Sarkar, F. H.; Wang, Z. Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat. Rev. 2013, 39, 640-646.
31. Kang, Y.; Massague, J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118, 277-279.
32. Sarkar, F. H.; Li, Y.; Wang, Z.; Kong, D. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev. 2010, 29, 383-394.
33. Rhim, A. D.; Mirek, E. T.; Aiello, N. M.; Maitra A.; Bailey, J. M.; McAllister, F.; Reichert, M.; Beatty, G. L.; Rustgi, A. K.; Vonderheide, R. H.; Leach, S. D.; Stanger, B. Z. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148, 349-361.
34. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A. S.; Ali, S.; Abbruzzese, J. L.; Gallick, G. E.; Sarkar, F. H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer.;ells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69, 2400-2407.
35. Xie, M.; Zhang, L.; He, C. S.; Xu, F.; Liu, J. L.; Hu, Z. H.; Zhao, L. P.; Tian, Y. Activation of Notch-1 enhances epithelialmesenchymal transition in gefitinib-acquired resistant lung cancer cells. J. Cell. Biochem. 2012, 113, 1501-1513.
36. Ahmad, A.; Wang, Z.; Kong, D.; Ali, R.; Ali, S.; Banerjee, S.; Sarkar, F. H. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res, Treat. 2011, 126, 15-25.
37. Kong, D.; Wang, Z.; Sarkar, S. H.; Li, Y.; Banerjee, S.; Saliganan, A.; Kim, H. R.; Cher, M. L.; Sarkar, F. H. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008, 26, 1425-1435.
38. Bao, B.; Wang, Z.; Ali, S.; Kong, D.; Li, Y.; Ahmad, A.; Banerjee, S.; Azmi, A. S.; Miele, L.; Sarkar, F. H. Notch-1 induces epithelialmesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011, 307, 26-36.
39. Shah, A. N.; Summy, J. M.; Zhang, J.; Park, S. I.; Parikh, N. U.; Gallick, G. E. Development and characterization of gemcitabineresistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14, 3629-3637.
40. Stoyianni, A.; Goussia, A.; Pentheroudakis, G.; Siozopoulou, V.; Ioachim, E.; Krikelis, D.; Golfinopoulos, V.; Cervantes, A.; Bobos, M.; Fotsis, T.; Bellou, S.; Fountzilas, G.; Malamou-Mitsi, V.; Pavlidis, N. Immunohistochemical study of the epithelialmesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. Anticancer Res. 2012, 32, 1273-1281.
41. Huang, Y.; Hoque, M. O.; Wu, F.; Trink, B.; Sidransky, D.; Ratovitski, E. A. Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle 2008, 7, 1613-1622.
42. Gungor, C.; Zander, H.; Effenberger, K. E.; Vashist, Y. K.; Kalinina, T.; Izbicki, J. R.; Yekebas, E.; Bockhorn, M. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res. 2011, 71, 5009-5019.
43. Matsuno, Y.; Coelho, A. L.; Jarai, G.; Westwick, J.; Hogaboam, C. M. Notch signaling mediates TGF-beta1-induced epithelialmesenchymal transition through the induction of Snai1. Int. J. Biochem. Cell Biol. 2012, 44, 776-789.
44. Chen, Y.; Zheng, S.; Qi, D.; Zheng, S.; Guo, J.; Zhang, S.; Weng, Z. Inhibition of Notch signaling by a gamma-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS One 2012, 7, e46512.
45. Gupta, N.; Xu, Z.; El-Sehemy, A.; Steed, H.; Fu, Y. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. Gynecol. Oncol. 2013.
46. Ohashi, S.; Natsuizaka, M.; Naganuma, S.; Kagawa, S.; Kimura, S.; Itoh, H.; Kalman, R. A.; Nakagawa, M.; Darling, D. S.; Basu, D.; Gimotty, P. A.; Klein-Szanto, A. J.; Diehl, J. A.; Herlyn, M.; Nakagawa, H. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res. 2011, 71, 6836-6847.
47. Kuphal, S.; Palm, H. G.; Poser, I.; Bosserhoff, A. K. Snailregulated genes in malignant melanoma. Melanoma Res. 2005, 15, 305-313.
48. Mikaelian, I.; Blades, N.; Churchill, G. A.; Fancher, K.; Knowles, B. B.; Eppig, J. T.; Sundberg, J. P. Proteotypic classification of spontaneous and transgenic mammary neoplasms. Breast Cancer Res. 2004, 6, R668-R679.
49. Kang, M.; Jiang. B.; Xu, B.; Lu, W.; Guo, Q.; Xie, Q.; Zhang, B.; Dong, X.; Chen, D.; Wu, Y. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Cancer Lett. 2013, 330, 11-21.
50. Zavadil, J.; Cermak, L.; Soto-Nieves, N.; Bottinger, E. P. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-tomesenchymal transition. EMBO J. 2004, 23, 1155-1165.
51. Nyhan, K. C.; Faherty, N.; Murray, G.; Cooey, L. B.; Godson, C.; Crean, J. K.; Brazil, D. P. Jagged/Notch signalling is required for a subset of TGFbeta1 responses in human kidney epithelial cells. Biochim. Biophys. Acta. 2010, 1803, 1386-1395.
52. Leong, K. G.; Niessen, K.; Kulic, I.; Raouf, A.; Eaves, C.; Pollet, I.; Karsan, A. Jagged1-mediated Notch activation induces epithelialto-mesenchymal transition through Slug-induced repression of Ecadherin. J. Exp. Med. 2007, 204, 2935-2948.
53. Chen, J.; Imanaka, N.; Griffin, J. D. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br. J. Cancer 2010, 102, 351-360.
54. Kabashima-Niibe, A.; Higuchi, H.; Takaishi, H.; Masugi, Y.; Matsuzaki, Y.; Mabuchi, Y.; Funakoshi, S.; Adachi, M.; Hamamoto, Y.; Kawachi, S.; Aiura, K.; Kitagawa, Y.; Sakamoto, M.; Hibi, T. Mesenchymal stem cells regulate epithelialmesenchymal transition and tumor progression of pancreatic cancer cells. Cancer Sci. 2013, 104, 157-164.
55. Tanaka, S.; Shiraha, H.; Nakanishi, Y.; Nishina, S.; Matsubara, M.; Horiguchi, S.; Takaoka, N.; Iwamuro, M.; Kataoka, J.; Kuwaki, K.; Hagihara, H.; Toshimori, J.; Ohnishi, H.; Takaki, A.; Nakamura, S.; Nouso, K.; Yagi, T.; Yamamoto, K. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int. J. Cancer 2012, 131, 2537-2546.
56. Brabletz, S.; Bajdak, K.; Meidhof, S.; Burk, U.; Niedermann, G.; Firat, E.; Wellner, U.; Dimmler, A.; Faller, G.; Schubert, J.; Brabletz, T. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011, 30, 770-782.
57. Yang, Y.; Ahn, Y. H.; Gibbons, D. L.; Zang Y.; Lin, W.; Thilaganathan, N.; Alvarez, C. A.; Moreira, D. C.; Creighton, C. J.; Gregory, P. A.; Goodall, G. J.; Kurie, J. M. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J. Clin. Invest. 2011, 121, 1373-1385.
58. Xing, F.; Okuda, H.; Watabe, M.; Kobayashi, A.; Pai, S. K.; Liu, W.; Pandey, P. R.; Fukuda; K.; Hirota, S.; Sugai, T.; Wakabayshi, G.; Koeda, K.; Kashiwaba, M.; Suzuki, K.; Chiba, T.; Endo, M.; Mo, Y. Y.; Watabe, K. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 2011, 30, 4075-4086.
59. Caiado, F.; Carvalho, T.; Rosa, I.; Remédio, L.; Costa, A.; Matos, J.; Heissig, B.; Yagita, H.; Hattori, K.; da Silva, J. P.; Fidalgo, P.; Pereira, A. D.; Dias, S. Bone marrow-derived CD11b+Jagged-2+ cells promote epithelial to mesenchymal transition and metastization in colorectal cancer. Cancer Res. 2013, 73(14), 4233-4246.
60. Espinoza, I.; Miele, L. Notch inhibitors for cancer treatment. Pharmacol. Ther. 2013, 139(2), 95-110
61. Palagani, V.; El, Khatib. M.; Kossatz, U.; Bozko, P.; Müller, M. R.; Manns, M. P.; Krech, T.; Malek, N. P.; Plentz, R. R. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by gamma-secretase inhibitor IX. PLoS One 2012, 7, e46514.
62. Purow, B. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol. 2012, 727, 305-319.
63. Wang, Z.; Zhang, Y.; Banerjee, S.; Li, Y.; Sarkar, F. H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006, 106, 2503-2513.
64. Wang, Z.; Zhang, Y.; Banerjee, S.; Li, Y.; Sarkar, F. H. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int. J. Cancer 2006, 118, 1930-1936.
65. Li, Y.; VandenBoom, T. G. 2nd.; Kong, D.; Wang, Z.; Ali, S.; Philip, P. A.; Sarkar, F. H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69, 6704-6712.